Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | CTSC | P53634 | 2/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.34 |
| ▸ | GRB2 | P62993 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | TACR2 | P21452 | 1/20 | 0.33 |
| ▸ | APC | P25054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2893127 | 1.00 | ECE1 (0.38) | ECE1ITGA4ITGB7RETCTSK | |
| SCHEMBL9886055 | 0.93 | CTSC (0.41) | ECE1ITGA4ITGB7RETCTSK | |
| SCHEMBL16485802 | 0.91 | ECE1 (0.38) | ECE1ITGA4ITGB7RETCTSK | |
| SCHEMBL16478325 | 0.89 | ECE1 (0.42) | ECE1ITGA4ITGB7CTSKCTSC | |
| SCHEMBL16485782 | 0.88 | CTSC (0.48) | RETCTSKCTSCCTSS | |
| SCHEMBL16485757 | 0.86 | ECE1 (0.40) | ECE1ITGA4ITGB7RETCTSK | |
| SCHEMBL299126 | 0.82 | CTSC (0.43) | ECE1ITGA4ITGB7CTSKCTSC | |
| SCHEMBL16485771 | 0.81 | CTSC (0.38) | ECE1ITGA4ITGB7CTSKCTSC | |
| SCHEMBL2892969 | 0.81 | CTSC (0.48) | ITGA4ITGB7RETCTSKCTSC | |
| SCHEMBL2892971 | 0.81 | CTSC (0.48) | ITGA4ITGB7RETCTSKCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329775-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | FORD RHONAN (GB) | 2012-12-27 | — | — | US | disclosed |
| US-8193239-B2 | Substituted 1-cyanoethylheterocyclylcarboxamide compounds | ASTRAZENECA AB (SE) | 2012-06-05 | — | — | US | disclosed |
| WO-2011154677-A1 | SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE COMPOUNDS - 760 | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011154677-A1 | SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE COMPOUNDS - 760 | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | WO | disclosed |
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR2 | ECE1 78/4885ITGA4 3092/4885ITGB7 2926/4885 |
| US-20120329775-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR2 | ECE1 78/4885ITGA4 3092/4885ITGB7 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.